Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | EML4 - ALK ALK K1150dup |
| Therapy | Lorlatinib |
| Indication/Tumor Type | lung adenocarcinoma |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| EML4 - ALK ALK K1150dup | lung adenocarcinoma | predicted - resistant | Lorlatinib | Case Reports/Case Series | Actionable | In a clinical case study, ALK K1150dup was identified at the time of progression on Lorbrena (lorlatinib) in a patient with lung adenocarcinoma harboring EML4-ALK (PMID: 42129432). | 42129432 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (42129432) | The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib. | Full reference... |